Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Long-Term Deferred Tax (2022 - 2023)

Bicycle Therapeutics' Long-Term Deferred Tax history spans 2 years, with the latest figure at $4.9 million for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax fell 92.63% year-over-year to $4.9 million; the TTM value through Dec 2023 reached $4.9 million, down 92.63%, while the annual FY2023 figure was $4.9 million, 92.63% down from the prior year.
  • Long-Term Deferred Tax reached $4.9 million in Q4 2023 per BCYC's latest filing, down from $66.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $66.3 million in Q4 2022 to a low of $4.9 million in Q4 2023.